Glycemic control in type 2  diabetes—how low should you go?

This activity is provided by Haymarket Medical Education.

Faculty
Richard Aguilar, MD
Joel Zonszein, MD, CDE, FACE, FACP

Release Date: April 8, 2015
Expiration Date: April 8, 2016
Estimated time to complete the educational activity: 60 minutes

Statement of Need: Recent updates to the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) guidelines have focused on the need for more intensive therapy in patients with type 2 diabetes mellitus (T2DM) to reach and maintain glycemic control. The shift in guideline recommendations away from a “one size fits all” approach and toward a more personalized, patient-centered approach to management of T2DM, with less focus on achieving strict HbA1C targets and more focus on minimizing micro- and macrovascular complications, has been a source of debate among clinicians and a challenge to implement.This monograph will focus on key topics of this debate, with two physicians who are leaders in the field, Dr. Richard Aguilar and Dr. Joel Zonszein, presenting their thoughts on the subject and strategies for implementation in clinical practice.

Target Audience: This activity has been designed to meet the educational needs of family physicians, internal medicine specialists, nurse practitioners, physician assistants, and any healthcare providers who manage patients with T2DM.

Learning Objectives: After completing the activity, the participant should be better able to:

Analyze the supporting and opposing views surrounding aggressive lowering of HbA1c, personalized, patient-centered approaches to managing type 2 diabetes mellitus (T2DM), and early initiation of pharmacologic treatment
Evaluate the barriers and benefits associated with newer pharmacological agents for treatment of T2DM
Implement select aspects of the ADA/EASD guidelines in the individualized treatment of T2DM patients

Accreditation Statements

Physician Credit: Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Academy of Physician Assistants (AAPA)

The AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hour of Category I credit for completing this program.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME/CE activity:

Faculty Disclosures

Name of Faculty	Financial Relationship
Richard Aguilar, MD	Speaker’s Bureau and Advisory Board for Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals and Takeda Pharmaceuticals of America
Joel Zonszein, MD, CDE, FACE, FACP	Consultant and Advisory Boards for NovoNordisk, Takeda Pharmaceuticals, and Boehringer Ingelheim, Speaker’s Bureau for NovoNordisk and Takeda Pharmaceuticals

Staff/Planners’ Disclosures

The planners and managers for this program reported the following financial relationships with commercial interests whose products or services may be related to the content of this CME activity:HME planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use: This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Haymarket Medical Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation: There are no fees for participating in and receiving CME/CE credit for this activity. During the period of April 8, 2015, through April 8, 2016, participants must:

Read the learning objectives and faculty disclosures;
Complete the pre-assessment test;
Study the educational activity;
Submit the post-test online (clinicians may register at www.mycme.com);
Complete the evaluation form online

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities